Table 4.
Relation of UBQLN1 expression and different clinicopathologic characteristic
| UBQLN1 | P | ||
|---|---|---|---|
| High expression (%) | Low expression (%) | ||
| Gender | |||
| male | 28(56.0) | 22(44.0) | 0.499 |
| female | 24(63.2) | 14(36.8) | |
| Age(y) | |||
| ≤60 | 21(55.3) | 17(44.3) | 0.524 |
| >60 | 31(62.0) | 19(38.0) | |
| Diameter(cm) | |||
| <3 | 16(80.0) | 4(20.0) | 0.032* |
| ≥3 | 30(52.6) | 27(47.4) | |
| Clinical stage | |||
| Early | 31(57.4) | 23(42.6) | 0.686 |
| Advanced | 21(61.8) | 13(38.2) | |
| LM | |||
| Yes | 21(60.0) | 14(40.0) | 0.672 |
| NO | 17(54.8) | 14(45.2) | |
| DM | |||
| Yes | 2(100.0) | 0(0.0) | 0.511 |
| No | 50(58.1) | 36(41.9) | |
| ALK expression | |||
| Yes | 7(77.8) | 2(22.2) | 0.471 |
| No | 43(60.6) | 28(39.4) | |
| EGFR mutation | |||
| Yes | 13(65.0) | 7(35.0) | 0.541 |
| No | 39(57.4) | 29(42.6) | |
| PDL1 expression | |||
| Yes | 43(63.2) | 25(36.8) | 0.098 |
| No | 6(40.0) | 9(60.0) | |
Early: early LC, Advanced: advanced LC, LM Lymph node metastasis, DM distant metastasis
*There are significant difference among different groups